Scholarlink

Objective <p>To systematically map the global landscape, evolution and key characteristics of interventional clinical trials in pulmonary fibrosis, providing an empirical basis for future trial strategies and resource allocation.</p> Methods <p>The INFORMA Pharma Intelligence database was searched to identify 1,203 interventional PF trials. Descriptive statistics were applied to analyse temporal trends, geographic distribution, sponsors, trial phase and status, primary endpoints, drug targets or mechanisms, and the disease spectrum.</p> Results <p>Global pulmonary fibrosis trial activity displayed a three-stage growth pattern, with a surge in 2020. Research is highly concentrated geographically: the United States (316 trials) and China (285 trials) dominate, yet only 128 trials are multinational. The pipeline remains centred on nintedanib (94 trials) and pirfenidone (88 trials), while target diversity is expanding, especially toward anti-angiogenic and multi-tyrosine-kinase inhibitors. Primary endpoints focus on safety or tolerability and Forced Vital Capacity change. The disease spectrum has broadened from idiopathic pulmonary fibrosis to include Connective tissue disease-associated fibrosis.</p> Conclusions <p>Pulmonary fibrosis clinical research is experiencing unprecedented dynamism and diversification, transitioning from targeted therapy towards precision and multimodal intervention. Enhanced international collaboration, optimized trial design, and deeper precision-based stratification will be critical to advancing the field from slowing disease progression to reversing tissue damage.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global landscape for pulmonary fibrosis treatment: a data-driven perspective from clinical trials

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月18日

查看全文
  • Chunyan Zhao,
  • Chang Song,
  • Yue Zhou,
  • Jing Luo,
  • Shaochu Zheng,
  • Xiaojuan Li,
  • Yuhai Dang,
  • Nuo Yang,
  • Jinliang Kong

摘要

Objective

To systematically map the global landscape, evolution and key characteristics of interventional clinical trials in pulmonary fibrosis, providing an empirical basis for future trial strategies and resource allocation.

Methods

The INFORMA Pharma Intelligence database was searched to identify 1,203 interventional PF trials. Descriptive statistics were applied to analyse temporal trends, geographic distribution, sponsors, trial phase and status, primary endpoints, drug targets or mechanisms, and the disease spectrum.

Results

Global pulmonary fibrosis trial activity displayed a three-stage growth pattern, with a surge in 2020. Research is highly concentrated geographically: the United States (316 trials) and China (285 trials) dominate, yet only 128 trials are multinational. The pipeline remains centred on nintedanib (94 trials) and pirfenidone (88 trials), while target diversity is expanding, especially toward anti-angiogenic and multi-tyrosine-kinase inhibitors. Primary endpoints focus on safety or tolerability and Forced Vital Capacity change. The disease spectrum has broadened from idiopathic pulmonary fibrosis to include Connective tissue disease-associated fibrosis.

Conclusions

Pulmonary fibrosis clinical research is experiencing unprecedented dynamism and diversification, transitioning from targeted therapy towards precision and multimodal intervention. Enhanced international collaboration, optimized trial design, and deeper precision-based stratification will be critical to advancing the field from slowing disease progression to reversing tissue damage.